Do you want to read an article? Please log in or register.
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Multiple Myeloma (MM)
Indications
Related content
Multiple Myeloma (MM)
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Blood Cancer J
Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD Jr, Lee HC
doi: 10.1038/s41408-025-01414-6
Multiple Myeloma (MM)
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Blood Cancer J
Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD Jr, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A
doi: 10.1038/s41408-025-01297-7
Multiple Myeloma (MM)
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium
Blood Cancer J
Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ
doi: 10.1038/s41408-026-01469-z
Skin Cancer
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Eur J Cancer
Lallas K, Nanz L, Ugurel S, Mohr P, Meier F, Weichenthal M, von Wasielewski I, Terheyden P, Hassel J, Kreuter A, Herbst R, Gesierich A, Pföhler C, Gutzmer R, Welzel J, Gebhardt C, Haferkamp S, Ulrich J, Kaatz M, Meiss F, Berking C, Gambichler T, Livingstone E, Zimmer L, Flatz L, Forschner A, Schadendorf D, Hillen U, Leiter U
doi: 10.1016/j.ejca.2026.116582
Multiple Myeloma (MM)
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent
Adv Ther
Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martínez López J, Rodríguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV
doi: 10.1007/s12325-025-03409-y
Multiple Myeloma (MM)
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis
Am J Hematol
Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann SM, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R
doi: 10.1002/ajh.70297
Multiple Myeloma (MM)
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma
Blood Cancer J
Kumar S, Jagannath S, Weisel KC, Rosiñol L, Leleu X, Dimopoulos MA, Kastritis E, Siegel DS, Monge J, Du J, de la Rubia J, Asensi Cantó P, Lee JH, Mateos MV, Puertas B, Gozzetti A, Dytfeld D, Ocio EM, Blade J, Ozaki S, Beksac M, Escalante F, Nagaraj M, Hassan R, Bonar N, Spin P, Shokoohi M, Siddiqui M, Wang D, Hou K, West MED, Hampp C, Green J, Humblet O, Breskin A, Harnett J, Ge W, Sobel RE, Jalbert JJ, Kroog GS, Rodriguez Lorenc K, Ma Q, Durie BGM
doi: 10.1038/s41408-026-01466-2
Multiple Myeloma (MM)
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Blood
Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, von Tresckow B, Wulf GG, Weisel KC, Blau I, Engelhardt M, Wäsch R, Schub N, Teipel R, Hecker JS, Waldschmidt JM, Besemer B, Baermann BN, Call S, Hansmann L, Ayuk FA, Raab MS, Einsele H, Platzbecker U, Kröger N
doi: 10.1182/blood.2025028330
Multiple Myeloma (MM)
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Blood Cancer J
Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y, Annyapu E, Dhakal B, Bhutani D, Thanendrarajan S, Zangari M, D'Souza A, Lentzsch S, van Rhee F, Chakraborty R, Schinke C, Mohan M, Shah MR
doi: 10.1038/s41408-025-01386-7